| A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) (NCT05358717) | Novartis Pharmaceuticals | 2022-06-03 |
| 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease (NCT05358821) | Supernus Pharmaceuticals, Inc. | 2022-05-26 |
| TEsting METformin Against Cognitive Decline in HD (NCT04826692) | Instituto de Investigacion Sanitaria La Fe | 2022-04-11 |
| Huntington's Disease Young Adult Study 2.0 (NCT06391619) | University College, London | 2022-04-06 |
| N- Homocysteinylated Huntingtin in Huntington's Disease (NCT05225051) | Central Hospital, Nancy, France | 2022-04-01 |
| Making HD Voices Heard (NCT05268029) | Huntington Study Group | 2022-03-23 |
| A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects (NCT05238701) | Luye Pharma Group Ltd. | 2022-02-25 |
| Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD (NCT04301726) | Fundacion Huntington Puerto Rico | 2022-01-21 |
| Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study (NCT06209515) | Kuopio University Hospital | 2022-01-01 |
| Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3) (NCT05126862) | University of Virginia | 2021-12-10 |
| Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease (NCT04713982) | Vanderbilt University Medical Center | 2021-11-19 |
| Move to Improve: Telehealth Exercise to Music for HD (NCT05270681) | Ohio State University | 2021-11-08 |
| Efficacy of Cognitive Rehabilitation Using Virtual Reality and Computer-based Cognitive Stimulation on Cognitive Impairment Associated to Movement Disorders (NCT05769972) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2021-10-13 |
| Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease (NCT05243017) | UniQure Biopharma B.V. | 2021-10-07 |
| Preparing for Prevention of Huntington's Disease (PREVENT-HD) (NCT04818060) | University of Wisconsin, Madison | 2021-09-13 |
| Non-invasive Brain Stimulation in Huntington's Disease (NCT04429230) | Western University, Canada | 2021-09-07 |
| Study of WVE-003 in Patients With Huntington's Disease (NCT05032196) | Wave Life Sciences USA, Inc. | 2021-09-06 |
| Clinicopathological MRI and CSF Correlates in Huntington's Disease. (NCT05534139) | Leiden University Medical Center | 2021-08-11 |
| Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease (NCT04885114) | Voyager Therapeutics | 2021-07-30 |
| IMarkHD: in Vivo Longitudinal Imaging of HD Pathology (NCT03434548) | King's College London | 2021-07-20 |
| Adapted Physical Activity Effect on Abilities and Quality of Life of Huntington Patients and Relatives During Rehab Stay (NCT04917133) | Assistance Publique - Hôpitaux de Paris | 2021-06-07 |
| Energy Balance in Huntington's Disease. A Multidisciplinary Study Approach for a Complex Problem (BEHD-EM) (NCT05250323) | Hospital Universitario de Burgos | 2021-05-14 |
| Characterization and Quantification of Motor Speech Disorders in Huntington's Disease: Identification of Acoustic Markers (NCT04630574) | University Hospital, Bordeaux | 2021-02-23 |
| iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626 (NCT03810898) | CHDI Foundation, Inc. | 2021-02-09 |
| Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study (NCT04421339) | The University of Texas Health Science Center, Houston | 2021-01-22 |
| Complex Eye Movements in Parkinson's Disease and Related Movement Disorders (NCT04925622) | Saccadous, Inc. | 2021-01-04 |
| PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD (NCT04556656) | Prilenia | 2020-10-16 |
| NIPD on cffDNA for Triplet Repeat Diseases (NCT04698551) | University Hospital, Montpellier | 2020-09-01 |
| Development of Assessments for Later Stage HD (NCT04370470) | CHDI Foundation, Inc. | 2020-09-01 |
| Risperidone for the Treatment of Huntington's Disease Involuntary Movements (NCT04201834) | University of Rochester | 2020-08-13 |
| Dosimetry of [11C]CHDI-180R and [11C]CHDI-626. (NCT05224115) | Universitaire Ziekenhuizen KU Leuven | 2020-07-17 |
| Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease (NCT04617847) | Wave Life Sciences USA, Inc. | 2020-04-13 |
| Symptomatic Therapy for Patients With Huntington's Disease (NCT04071639) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-03-12 |
| Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease (NCT04012411) | University Hospital, Montpellier | 2020-03-03 |
| Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients. (NCT04219241) | Azidus Brasil | 2020-02-10 |
| Deep Brain Stimulation Treatment for Chorea in Huntington's Disease (NCT04244513) | Beijing Municipal Administration of Hospitals | 2020-02-01 |
| Synaptic Density and Progression of Huntington's Disease. (NCT04701580) | Universitaire Ziekenhuizen KU Leuven | 2020-01-14 |
| Couple and Spouse Caregiver in Huntington's Disease (NCT04394767) | University Hospital, Lille | 2020-01-13 |
| Clinical Study to Monitor Plasma Levels of 24OHC in Subject with HD (NCT04257513) | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | 2019-10-31 |
| Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease (NCT04617860) | Wave Life Sciences USA, Inc. | 2019-09-24 |
| Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease (NCT03854019) | The University of Texas Health Science Center, Houston | 2019-08-05 |
| FuRST 2.0 Cognitive Pre-testing - Round 2 (NCT03709173) | CHDI Foundation, Inc. | 2019-08-02 |
| Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease (NCT03980938) | EIP Pharma Inc | 2019-07-08 |
| Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders (NCT04231487) | Rutgers, The State University of New Jersey | 2019-06-27 |
| Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products (NCT03886753) | Children's Hospital of Philadelphia | 2019-05-15 |
| An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies (NCT03842969) | Hoffmann-La Roche | 2019-04-23 |
| Mitochondrial Biomarkers in Huntington's Disease (NCT04515550) | University Hospitals Cleveland Medical Center | 2019-04-04 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B (NCT03787758) | Supernus Pharmaceuticals, Inc. | 2019-02-28 |
| Group Drum-Based Music Therapy Intervention for Parkinson's Disease/Huntington's Disease (NCT05157074) | Johns Hopkins University | 2019-01-09 |
| Nilotinib in Huntington's Disease (NCT03764215) | Georgetown University | 2018-11-15 |
| Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients (NCT03417583) | Vanderbilt University Medical Center | 2018-11-09 |
| Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease (NCT03599076) | BioSensics | 2018-09-25 |
| CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects (NCT03713892) | Chong Kun Dang Pharmaceutical | 2018-05-23 |
| PHysical Activity and Exercise Outcomes in Huntington's Disease (NCT03344601) | Cardiff University | 2018-02-16 |
| Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease (NCT03252535) | Azidus Brasil | 2018-01-15 |
| Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease (NCT02728115) | Azidus Brasil | 2017-10-16 |
| Is Caffeine an Environmental Modifier in Huntington's Disease? (NCT03034122) | University Hospital, Lille | 2017-10-11 |
| Metabolomic Study in Huntington's Disease (METABO-HD) (NCT03296176) | University Hospital, Angers | 2017-10-09 |
| Genetic Risk: Whether, When, and How to Tell Adolescents (NCT03421327) | Johns Hopkins University | 2017-09-01 |
| Retinal Imaging in Neurodegenerative Disease (NCT03233646) | Duke University | 2017-07-20 |
| Decoding Presymptomatic White Matter Changes in Huntington Disease (NCT03193099) | Institut National de la Santé Et de la Recherche Médicale, France | 2017-07-11 |
| Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease (NCT03515213) | University of California, Irvine | 2017-04-27 |
| Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies (NCT03052712) | Centre Hospitalier Universitaire, Amiens | 2016-09-09 |
| Measuring Cortisol Levels in Persons With Parkinson's (PD) (NCT02727270) | Oregon Health and Science University | 2016-06-01 |
| Beta Testing of a New Assessment in Huntington's Disease (HD) (NCT03119246) | Assistance Publique - Hôpitaux de Paris | 2016-06-01 |
| Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers (NCT02907294) | Palobiofarma SL | 2016-03-01 |
| Gait Analysis in Neurological Disease (NCT02994719) | Beth Israel Deaconess Medical Center | 2016-03-01 |
| Resveratrol and Huntington Disease (NCT02336633) | Assistance Publique - Hôpitaux de Paris | 2015-07-01 |
| A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease (NCT02453061) | Institut National de la Santé Et de la Recherche Médicale, France | 2015-06-29 |
| A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease (NCT02464293) | Lancaster University | 2015-06-01 |
| Characterization of the Profile of Dysarthria in Huntington's Disease, Using the Clinical Evaluation Battery of Dysarthria (NCT03142217) | Centre Hospitalier Universitaire, Amiens | 2015-03-26 |
| Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea. (NCT01834053) | Chaitanya Hospital, Pune | 2014-09-01 |
| Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD) (NCT02535884) | Heinrich-Heine University, Duesseldorf | 2014-07-01 |
| Behavioural Problems in Huntington Disease : Analysis and Enhancement of Caregiver and Patient Experience (NCT02218567) | University Hospital, Angers | 2014-06-01 |
| Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study (NCT02563418) | University Hospital, Angers | 2014-05-01 |
| A Pre-Cellular Therapy Observational Study in Early Huntington's Disease (NCT01937923) | University of California, Davis | 2013-08-01 |
| Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease (NCT01882062) | Institut National de la Santé Et de la Recherche Médicale, France | 2013-05-01 |
| Dance and Huntington Disease (NCT01842919) | Institut National de la Santé Et de la Recherche Médicale, France | 2013-04-01 |
| Effect of Tetrabenazine on Stroop Interference in HD (NCT01834911) | New York Medical College | 2013-03-01 |
| Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI) (NCT02819700) | Centre Hospitalier Universitaire, Amiens | 2013-01-29 |
| Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease (NCT01696708) | Institut National de la Santé Et de la Recherche Médicale, France | 2012-12-06 |
| Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease (NCT01590888) | Prana Biotechnology Limited | 2012-04-01 |
| Evaluating the Relationship of Morphine Consumption and Pain-related Molecules in Hepatic Surgical Patients (NCT01919034) | National Cheng-Kung University Hospital | 2012-04-01 |
| Biological Sample Collection for Research and Biobanking (NCT04270604) | New York Stem Cell Foundation Research Institute | 2012-02-06 |
| Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease (NCT01602900) | GlaxoSmithKline | 2011-11-22 |
| Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) (NCT01357681) | Charite University, Berlin, Germany | 2011-09-01 |
| A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease (NCT01458470) | University of British Columbia | 2011-09-01 |
| Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm (NCT02814201) | Centre Hospitalier Universitaire, Amiens | 2011-07-01 |
| 31P-MRS and Huntington Disease (NCT01359774) | Institut National de la Santé Et de la Recherche Médicale, France | 2011-04-01 |
| Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease (NCT01306929) | Prilenia | 2011-03-24 |
| An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196 (NCT01485952) | Siena Biotech S.p.A. | 2011-03-01 |
| An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease (NCT01085266) | Medivation, Inc. | 2010-02-01 |
| A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) (NCT00988624) | Pfizer | 2009-10-01 |
| Bioavailability of Ubiquinol in Huntington Disease (NCT00980694) | University of Rochester | 2009-09-01 |
| A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease (NCT00920946) | Medivation, Inc. | 2009-07-01 |
| Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. (NCT00970229) | Institute for Neurodegenerative Disorders | 2009-07-01 |
| Assessment of Social-emotional Functioning in Neurological Diseases (NCT01339130) | Centre Hospitalier Universitaire, Amiens | 2009-06-01 |
| Study of Huntington Patients in Connection With European Huntington's Disease Network (EHDN) (NCT01554033) | Seoul National University Hospital | 2009-05-01 |
| Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride (NCT00632645) | Assistance Publique - Hôpitaux de Paris | 2009-04-01 |
| A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions (NCT00870974) | Institute for Neurodegenerative Disorders | 2009-03-01 |